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GUIDELINES ON FIBRINOGEN ASSAYS
Haematology departments in the UK have traditionally
performed fibrinogen assays to detect decreased levels and
abnormalities of fibrinogen, and to assess haemorrhagic
risk. It has also been shown that elevated fibrinogen levels
are a predictor of a variety of arterial cardiovascular events,
and fibrinogen assays are sometimes recommended with
this in mind.
The Clauss fibrinogen assay (based on the thrombin
clotting time) is the most popular technique in UK hospital
laboratories, although many other methods are also in use.
There appears to be great variability in both the source of
reagents and the exact method used for the Clauss assay.
Most laboratories are now equipped with automated
coagulation analysers, and many of these perform a
fibrinogen estimation derived from the degree of change of
light scatter or optical density during the prothrombin time
(PT-Fg). A number of problems have been described in the
use of the PT-Fg method; it generally gives higher values
than the Clauss technique, but the exact degree of discrep-
ancy seems to depend on a number of different variables.
International and National standards are available for
fibrinogen, but do not appear to be universally used.
These guidelines have been prepared against this back-
ground and recommend which methods should be used in
various clinical settings, as well as highlighting a variety of
problems with fibrinogen assays.
INTRODUCTION
Fibrinogen is a major plasma protein (normal concentration
1Æ5–4Æ0 g ⁄ l), which is synthesized in the hepatocyte. It
comprises two each of three different polypeptide chains
(Aa, Bb and c) linked by disulphide bridges. Thrombin
cleaves the Aa and Bb chains to release fibrinopeptides A
and B, respectively, from the amino-terminal ends. After the
fibrinopeptides are released, the resulting fibrin monomers
undergo polymerization to form an insoluble fibrin clot
(Hantgan et al, 1994). Fibrinogen also shows heterogeneity
due to cleavage in the circulation, at the carboxyl termini of
the polypeptide chains, giving rise to a series of molecules of
varying size (de Maat et al, 1999). Fibrinogen and fibrin can
be degraded to progressively smaller fragments by proteo-
lytic enzymes, including plasmin and neutrophil elastase.
Fibrinogen is an acute phase reactant (Whicher & Dieppe,
1985; Hantgan et al, 1994) and levels may be raised in
relation to a variety of physiological variables and inflam-
matory conditions (Table I). The variation of fibrinogen
levels within the same normal subject has been observed to
be approximately 1Æ00 g ⁄ l in a study of 14 normal subjects
over a 3-year period, although in some of the subjects
fibrinogen levels varied by more than 2Æ5 g ⁄ l (Thompson
et al, 1987). Such variation must be taken into account
when fibrinogen is being considered as a risk factor for
ischaemic heart disease. One further pre-analytical variable
that has been reported to affect fibrinogen measurements,
which is relevant to epidemiological studies, is the season of
the year; fibrinogen levels are considerably higher in winter
(van der Bom et al, 1997). A seasonal difference of 0Æ34 g ⁄ l
(95% CI 0Æ29–0Æ30 g ⁄ l) was present in subjects aged
55–75 years which was more pronounced at age > 75 years.
A polymorphsim of the beta fibrinogen gene promoter
(G-455A) has been associated with increased levels of
fibrinogen (Humphries et al, 1999). Carriers of the A-allele
(about 20% of the population) have 7–10% higher fibrin-
ogen levels than those of the GG genotype. Reduced
fibrinogen levels may occur as a result of inherited gene
defects, resulting in abnormal, reduced or absent fibrinogen
protein, or as a result of liver disease or consumptive
coagulopathies.
THE ROLE OF FIBRINOGEN ASSAYS
Traditionally, fibrinogen assays have been required in the
investigation of haemorrhagic states or in laboratory testing
for haemorrhagic disorders (Table II). Some centres use a
fibrinogen assay along with the prothrombin time (PT) and
activated partial thromboplastin time (APTT), as part of a
general haemostatic screen. In this situation, the fibrinogen
level replaces the use of a thrombin clotting time, but the
information provided may differ depending on the type of
assay used. Whereas a sensitive thrombin time will detect
low fibrinogen levels, decreased fibrin monomer poly-
merization, abnormal fibrinopeptide release, and may be
influenced by acquired dysfibrinogens, heparin or fibrin ⁄
fibrinogen degradation products (FDP’s), different fibrinogen
assays show varying sensitivity to each of these factors.
Inherited fibrinogen defects
The rare conditions of congenital afibrinogenaemia, hypo-
fibrinogenaemia and dysfibrinogenaemia are due to gene
defects, resulting in reduced fibrinogen synthesis and release
and ⁄ or abnormal molecular species. In afibrinogenaemia,
there is a grossly decreased hepatic synthesis of fibrinogen,
with very low or undetectable plasma fibrinogen, which
results in a haemorrhagic diathesis, with prolonged clotting
times and abnormal platelet function. In hypofibrinogenae-
mia, circulating fibrinogen levels show a mild-to-moderate
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reduction, and patients may be asymptomatic or have
haemorrhagic problems. Dysfibrinogenaemia is character-
ized by abnormal fibrinogen function, therefore, immuno-
assays tend to give disproportionately higher levels than
clottable protein measurements. In some patients, hypodys-
fibrinogenaemia is present (reduced levels of fibrinogen
protein and abnormal function). Approximately 250
patients with dysfibrinogenaemia have been reported in
the literature, 55% of whom were asymptomatic, 25% of
whom had a haemorrhagic tendency and 20% of whom had
thrombophilia (Haverkate & Samama, 1995). The precise
incidence of inherited dysfibrinogenaemia is unclear, as
patients are usually detected because of a prolonged
thrombin clotting time and obviously this will only be
sensitive to certain types of fibrinogen abnormality.
Acquired fibrinogen defects
Acquired dysfibrinogens are usually due to excessive glyco-
sylation of the fibrinogen molecule and typically occur
in liver disease. In addition, in hepatocellular failure,
fibrinogen levels may be markedly reduced and fibrinogen
function may be influenced by the presence of elevated
levels of FDPs. In disseminated intravascular coagulation
(DIC), there is gross consumption of fibrinogen due to
generalized fibrin formation throughout the microvascula-
ture, and the presence of a variety of degraded forms of
fibrinogen and FDPs. Massive blood transfusion or the use of
colloids may also result in decreased fibrinogen levels as a
result of haemodilution.
Systemic thrombolytic therapy results in a gross reduc-
tion in fibrinogen levels and there is a high risk of
haemorrhage. Prior to starting a prolonged infusion (over
more than 1 d) of a plasminogen activator, and serially after
starting therapy, the fibrinogen level may be monitored as
an indication of appropriate therapy (target 0Æ5–1Æ0 g ⁄ l;
Ludlam et al, 1995). In some patients receiving thrombo-
lytic therapy, a fall in fibrinogen does not occur and an
adjustment of therapy is necessary to prevent venous
thrombotic extension (Marder & Sherry, 1988).
Increased fibrinogen
Elevated fibrinogen levels are also clinically relevant.
Fibrinogen is a major plasma protein and, therefore, a
small elevation in fibrinogen level will have a significant
impact on plasma viscosity, and thereby modify blood
rheology. Increased plasma viscosity (e.g. in hyperviscosity
syndrome) has been associated with an increased risk of
thromboembolism. In recent years, a number of large
prospective studies have shown that the fibrinogen level is a
predictor of a variety of cardiovascular events, including
stroke, myocardial infarction, leg ischaemia (in arterial
disease) and postsurgical arterial re-occlusion (Lowe &
Rumley, 1999). This statistical association has remained
significant regardless of the type of fibrinogen assay
employed, although some authors have suggested that
immunological assays may be better predictors of cardio-
vascular disease than functional assays (Cremer et al, 1994;
Sweetnam et al, 1996, 1998). However, the interpretation
of a fibrinogen value at the upper end of the normal range,
or of an elevated fibrinogen measurement, in an individual
patient is often difficult because of the genetic, physiological
and other factors outlined above (Machin & Mackie, 1993).
It is not known whether all types of fibrinogen assay are
equally sensitive to the increased fibrinogen levels resulting
from these different conditions. The various fibrinogen
assays may have a quite different sensitivity and clinical
utility when used on an individual patient basis.
THE MEASUREMENT OF FIBRINOGEN
A variety of different tests and assays of fibrinogen have
been used by clinical laboratories (for review see de Maat
et al, 1999). The assays vary in the degree of expertise and
time required, and the equipment available. Some tests are
designed for emergency situations, where an exact fibrin-
ogen level may not be required but merely an estimate of
whether the levels are normal or grossly decreased. The
expanded range of coagulation automation and reagents
has had a varying impact on the performance of laboratory
Table I. The physiological, pathological and lifestyle factors influ-
encing fibrinogen level.*
Elevated fibrinogen
Increasing age and female sex
Season
Pregnancy and oral contraception
Post-menopausal women
Acute phase reaction
Smoking
Acute exercise
Disseminated malignancy
Reduced fibrinogen
Afibrinogenaemia, hypofibrinogenaemia
Decompensated liver disease
Viral hepatitis
DIC
Haemodilution
*(Eliasson et al, 1993; Hantgan et al, 1994; Lowe et al, 1997;
Kluft & Lansink, 1997; van der Bom et al, 1997; Humphries et al,
1999).
Table II. The clinical utility of fibrinogen assays.
Investigation of a haemorrhagic state (afibrinogenaemia, hypo-
fibrinogenaemia, acquired or congenital dysfibrinogenaemia)
Investigation of unexpected prolonged ⁄ abnormal coagulation tests
Detection of DIC
The establishment and monitoring of prolonged thrombolytic
therapy
During Arvin therapy
Risk assessment profiling for arterial disease
Commercial use (diagnostics industry, pharmaceutical industry,
blood transfusion service) for quality monitoring and potency
assignment (e.g. factor VIII and fibrinogen concentrates)
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tests and their precision. Automated coagulometers utilize
different technologies to detect fibrin clot end-points. Some
employ mechanical principles involving the movement of a
metal hook or clot impedance of a ball bearing in a
magnetic field; others use photo-optical devices to measure
changes in light transmission or light scatter through 90.
Coagulation analysers that use a photo-optical detection
principle continuously monitor the change in optical
density or light scatter and the degree of change is
proportional to the fibrinogen concentration: hence the
derived fibrinogen assay. The most reliable derived fibrin-
ogen methods are based on the prothrombin time (PT-Fg),
where there is rapid thrombin generation and fibrin
formation.
TYPES OF FIBRINOGEN ASSAY
Clauss assays
A high concentration of thrombin (ranging from 35 to
200 U ⁄ml, but typically about 100 U ⁄ml) is added to dilute
test plasma and the clotting time is measured (Clauss,
1957). The test result is compared with a calibration curve
prepared by clotting a series of dilutions of a reference
plasma sample of known fibrinogen concentration, and a
result in g ⁄ l is obtained. The technique is relatively time
consuming and requires a high degree of technical expertise
if performed by manual methods, as the end-point is very
difficult to determine at the higher dilutions of standard
plasma, in test samples with low fibrinogen content, or in
samples forming friable clots. Mechanical end-point tech-
niques depend on the tensile strength of the clot and,
although this makes them sensitive at low fibrinogen
concentrations, they are particularly affected by heparin
therapy. Photo-optical systems depend on the change in
optical density resulting from fibrin formation, which
decreases light transmission and increases scattered light.
These methods are usually suitable for detecting weak fibrin
formation, but may give erroneous values when fibrin
monomer polymerization is slow. They are often affected by
turbid or lipaemic plasmas, while the light transmission
may be affected by bile pigment and free haemoglobin,
depending on the wavelength used by the optical system.
Most laboratories now use commercial reagents and an
automated method, and a multiplicity of products are
available, varying in thrombin strength, buffer composition
(inclusion of inhibitors of heparin and FDP’s), calibration
method and dilution range. The reagents in common use in
the UK have been evaluated (MDA, 2000; Mackie et al,
2002) and only small differences in fibrinogen levels were
observed. There were significant differences in Clauss
estimations depending on the analyser used, but these are
unlikely to have a clinical impact (0Æ1 g ⁄ l). A reasonable
degree of precision was obtained with normal plasma
[coefficient of variation (CV) typically 3–7% by optical
methods and 6–9% by mechanical]. The performance of
Clauss fibrinogen assays by fully automated coagulometers
in routine clinical laboratories may decrease the throughput
for samples requiring only PT and APTT, and many
laboratories only perform them when there is a special
indication. There is also the potential on some analysers for
reagent carry-over, as the Clauss assay uses a high
concentration of thrombin, which has the propensity of
sticking to foreign surfaces and may contaminate subse-
quent tests (e.g. PT, APTT), resulting in a false shortening of
clotting times.
The standard plasma or calibrant must be carefully
selected, as very turbid reference plasmas may cause poor
linearity on photo-optical coagulometers and poor parallel-
ism with serial dilutions of test plasmas (MDA, 1999). This
may lead to incorrect potency assignment, particularly for
samples with low fibrinogen levels, when single-point assays
are performed. Some commercial reference plasmas de-
signed for use in Clauss assays, appear to be erroneously
calibrated when compared with the International Standard.
This may reflect the calibration method used by the
manufacturer or the use of calibrants other than the
International Standard.
Recommendations
Although there is generally little impact of reagent system
or analyser on the Clauss assay, certain clinical subgroups
(e.g. DIC, thrombolytic therapy) may show greater discrep-
ancies, probably as a result of the thrombin concentration
and buffer composition (which will influence the impact of
heparin and FDP’s). Where possible, assays should not be
performed on samples collected within 4 h of administration
of therapeutic doses of unfractionated heparin, or on
samples collected from heparin-contaminated venous or
arterial lines. This may be a particular problem during
cardiopulmonary bypass or renal dialysis procedures, and in
these situations it may be necessary to remove the heparin
using suitable ion exchange resins or heparinase enzymes.
The reagent must only be used during its stated period of
stability, and care should be taken that pH changes do not
occur as a result of the reagent vial remaining open to the
air for prolonged periods. If single calibration curves are
used for the lifespan of the reagent, ensure that the reagent
is still stable ⁄ viable for the entire period. Quality control
samples should be used to check for temporal drift. As most
Clauss reagents contain high concentrations of thrombin,
appropriate cleaning methods should be employed on the
reagent delivery system of the analyser to avoid carry-over.
An optically clear fibrinogen standard is desirable to
avoid loss of linearity on some analysers. A suitable dilution
range must be used (this will vary depending on the
calibrant, reagent and analyser) and the calibration curve
must be linear (this normally requires logarithmic trans-
forms). The calibration curve must include at least three
(but preferably five) dilutions of the plasma, and duplicate
clotting times are advised. Test samples should be re-diluted
if they are outside the linear range of the assay. Use a single
type of reagent kit, standard and analyser within the
laboratory, as the results may not be easily interchangeable
between methods.
PT-derived (PT-Fg) tests
Fibrinogen estimations derived from the prothrombin time
(PT-Fg) have been widely used in recent years (Vermylen
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et al, 1963; Natelson & Dooley, 1974; Becker et al, 1984;
Cambas et al, 1985; Chantarangkul et al, 1987; de Metz &
van Wersch, 1987; Hoffmann & Verhappen, 1988; Rossi
et al, 1988). The analyser is calibrated by performing a
prothrombin time on a plasma (or series of plasma dilutions)
of known fibrinogen concentration and by plotting a graph
of the optical change against fibrinogen concentration. The
optical change in each test sample is then converted to a
fibrinogen value. As the technique is an indirect measure-
ment of fibrinogen, the choice of calibrant or standard is
very important. The attraction of the PT-Fg method is that it
rapidly provides a fibrinogen value at no extra cost (other
than that of the PT reagents), and it is currently used in
approximately 50% of UK Haematology laboratories [UK
National External Quality Assessment Scheme (NEQAS) for
Blood Coagulation, 2000], although there is controversy
regarding the suitability for clinical use. PT-Fg assays are
really a collection of associated methods that vary depend-
ing on the method of calibration, type of analyser and
reagent, and optical clarity of calibrant and test plasmas, as
well as the nature of any coagulopathy present.
Calibration methods recommended by manufacturers
differ; they may involve single- or multiple-point calibration,
and the use of fresh normal pooled plasma of good optical
quality or lyophilized plasma with a PT-Fg-specific calibra-
tion value. It is difficult to achieve calibration in some PT-Fg
methods if the reference plasma has a high fibrinogen level
or excess turbidity (MDA, 1999). Reference and test plasmas
with high turbidity tend to show an increased discrepancy
between PT-Fg and Clauss assays (Mackie et al, 2002).
Some, if not all, PT-Fg methods give higher values than
the Clauss technique (Palareti et al, 1991; Chantarangkul
et al, 1994; Chitolie et al, 1994, 1998; Kitchen et al, 1995;
Lawrie et al, 1998; MDA, 2000; Mackie et al, 2002). This
phenomenon has been observed in samples from patients
with DIC, liver disease, renal disease, dysfibrinogenaemia,
high fibrinogen levels and in those receiving anticoagulants,
or thrombolytic therapy. In clinical samples, the discrep-
ancy is not consistent over the entire range of observed
fibrinogen values and may depend on the nature of the
clinical group as well as the thromboplastin reagent used.
Some laboratories have found apparently normal fibrinogen
levels by PT-Fg, but reduced results by the Clauss assay in
patients with dysfibrinogenaemia or those receiving throm-
bolytic therapy. In these groups, it is unclear which method
correlates best with in vivo haemostasis. Other workers have
found a good comparability between Clauss and particular
types of PT-Fg assays (Rossi et al, 1988; de Cristofaro &
Landolfi, 1998); however, the latter stated that precision
was inadequate in PT-Fg assays if either the PT was
prolonged (e.g. as a result of anticoagulants) or the
fibrinogen level was high.
Recent multicentre studies (MDA, 1999, 2000; Mackie
et al, 2002) have shown that PT-Fg results vary according
to the reagent and analyser (even between different models
from the same manufacturer). A higher level of imprecision
(CV typically 6–12% for normal plasma) was seen compared
with Clauss assays, particularly if turbid reagents and
reference plasmas were used. In thrombolytic therapy,
fibrinogen degradation products (which were formed in
excess of fibrin split products) interfered in the Clauss assay,
but not in PT-Fg. Degraded fibrinogen molecules may
reduce fibrin polymerization by termination of the fibrin
chain, as they retain at least one fibrinopeptide A domain
(Nieuwenhuizen & Bos, 1999). The resulting weak, diffuse
clot formation and delayed clot detection would affect the
Clauss technique, while a large opacity change would still
eventually occur, giving a higher PT-Fg level. This effect
would be accentuated as the fibrinogen level fell, and by the
dilution effect seen in Clauss assays. Intermediate and late
FDPs cause a dose-dependent decrease in Clauss fibrinogen
and an increase in PT-Fg (Oosting & Hoffmann, 1997).
More turbid fibrin gels are generated at lower thrombin
concentrations (de Cristofaro & Landolfi, 1998). As the
thrombin concentration generated in the PT-Fg method is
substantially lower (on a U ⁄ml basis) than that typically
used in the Clauss assay, while the fibrinogen concentration
is 2Æ5–5-fold higher, the fibrin gels generated by the PT-Fg
method will be more turbid. This may particularly influence
the results under conditions of abnormal fibrin polymeriza-
tion.
PT-Fg results on clinical samples, particularly those with
abnormal fibrinogen molecules and either high or low
fibrinogen levels, show a sigmoid relationship with Clauss
and other functional assays (Chitolie et al, 1998; MDA,
1999, 2000; Mackie et al, 2002). The plateau of the
sigmoid curve differs depending on the PT-Fg thromboplas-
tin reagent, reducing the upper limit of detection by as
much as 2 g ⁄ l (at equivalent Clauss values of 5–6 g ⁄ l). It is
not known whether the upper cut-off limits vary between all
reagents or whether there is a significant batch dependency.
This problem precludes the use of simple data correction
(algorithm) equations to normalize the PT-Fg results to
Clauss values.
Recommendations
PT-Fg assays are not recommended for general use in
Haematology laboratories. As both the analyser and reagent
influence PT-Fg values, each reagent ⁄ instrument combina-
tion must be regarded as a separate assay type. The results
from different instruments or thromboplastin reagents
should not be mixed and separate reference ranges are
required. PT-Fg assays are only suitable for samples with
good optical clarity, where a normal fibrinogen value can be
predicted, such as large epidemiological studies of normal
populations, where an accurate measurement of either
normal or elevated fibrinogen might not be required. In this
setting, as well as external quality assessment exercises, it is
important that data from different PT-Fg assays are not
pooled. Where PT-Fg assays have been used, there may be
difficulty in the subsequent interpretation of fibrinogen
results from patient records, as the results are not inter-
changeable between laboratories or hospitals because of the
differences between instrumentation and reagents. The
reference plasma must be carefully selected for optical
clarity, and calibration values must be available in relation
to the International Standard (either directly or indirectly).
Where necessary, local plasma pools should be calibrated
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against the International Standard in a Clauss assay and the
observed value should be used in the PT-Fg calibration
procedure.
Clottable protein
These assays are very accurate and have been used as
reference assays for fibrinogen. Thrombin is added to
plasma, in the absence of calcium ions, the clot is washed
and then dissolved in alkaline urea or other reagents,
followed by a spectrophotometric protein assay or estima-
tion (Ratnoff & Menzie, 1951; Jacobsson, 1955; Blomback &
Blomback, 1956; Swain & Feders, 1967; Gaffney & Wong,
1992). As the majority of the protein in the clot will be
fibrin, the protein concentration will be approximately
equivalent to the fibrinogen concentration. One convenient
method (Blomback & Blomback, 1956) is to measure the
absorbance at 282 nm and to calculate the fibrinogen
concentration using the extinction coefficient. Clottable
protein assays are time consuming, labour intensive and
technically difficult, making them unsuitable for routine use
in coagulopathy screening. However, they can be of
occasional use in the investigation of congenital fibrinogen
defects (Table III).
Immunological assay
A variety of immunological assays are available: enzyme-
linked immunosorbent assays (ELISAs), radial immunodif-
fusion and electrophoretic techniques, take many hours to
perform, the former giving the best accuracy and preci-
sion. Some clinical analysers (e.g. BN-100; Dade Behring,
Marburg, Germany) have a facility for fibrinogen assay
using immunonephelometry. All available immunological
assays have the disadvantage of measuring protein
concentration rather than functional activity. False esti-
mates may be obtained in some methods where degraded
forms of fibrinogen are present, as these have a different
antigenicity and may migrate at different rates in
immunodiffusion and electrophoresis techniques. These
effects are likely to explain the discrepancies between
fibrinogen antigen and either Clauss or PT-Fg results
observed in certain clinical groups.
Some commercial assays utilize monoclonal antibodies
directed against terminal regions of the fibrinogen molecule;
these allow the detection of intact (non-proteolysed) fibrin-
ogen or various specific types of degraded fibrinogen
molecule. Such assays are sometimes useful in research
studies or specialized investigations of individual patients.
Recommendations
ELISAs and immunonephelometric assays give comparable
results overall, although the latter has a high degree of
variability.
The Second International Standard for fibrinogen has
been calibrated by functional rather than immunological
methods. Until a directly calibrated standard becomes
available, the same standard should be used for both types
of fibrinogen assay and similar potency assumed. It is
essential that the same standard material be used for
different fibrinogen assays within an individual laboratory,
to avoid systematic error.
Fibrinogen antigen measurement is suitable for studies
assessing fibrinogen as a risk factor for cardiovascular
disease (Cremer et al, 1994; Sweetnam et al, 1996, 1998),
where normal or elevated fibrinogen levels are anticipated.
It also has utility in the investigation and differentiation of
congenital fibrinogen defects (Table III).
Other methods
The fibrinogen titre is an emergency test where plasma
(and, therefore, fibrinogen) is diluted in different types of
buffer, before the addition of thrombin (Mackie & Machin,
1989). The titre is reported as the last dilution to display a
clot after a given incubation time. The test can be performed
in the presence of various inhibitors, such as epsilon-amino-
N-caproic acid (EACA), to block plasmin, and protamine to
block heparin and FDP’s. However, the results are very
inaccurate, and the test is time consuming and does not
lend itself to automation. Owing to the widespread avail-
ability of automated analysers, the test has virtually
disappeared from clinical laboratories and it is not recom-
mended.
In gravimetric assays (Mackie & Machin, 1989), fibrin-
ogen is clotted from dilute plasma, using a strong thrombin
solution and calcium chloride. The clot is compressed to
express solution and non-clotted proteins, washed in saline,
and then dried and weighed on an accurate microbalance
(the number of available decimal places on the microbal-
ance obviously affects accuracy). The assay demands a
high degree of technical ability to obtain reproducible
results and is time consuming, as the clot must be com-
pletely dry before weighing. It is not, therefore, of clinical
utility when fibrinogen assays are required urgently. The
method does not lend itself to large numbers of tests,
cannot be automated and is not recommended for routine
use.
Sulphite precipitation techniques (Rampling & Gaffney,
1976) have been described, but are unreliable in some
clinical situations (particularly in patients with acute phase
reaction), and are not normally used in hospital haematol-
ogy laboratories.
PRE-TEST VARIABLES
The main pretest variables affecting fibrinogen assays are
summarized in Table IV. The recommended anticoagulant
for fibrinogen assay is tri-sodium citrate (World Health
Organization, 1999), at a strength of 0Æ105–0Æ109 mol ⁄ l
Table III. The recommended types of fibrinogen assay in different
clinical situations.
Bleeding diathesis Clauss
Congenital fibrinogen
defects
Clauss + clottable protein + immunoassay
DIC, acquired defects Clauss
High fibrinogen levels Clauss or immunoassay
Thrombolytic therapy Clauss
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(1 part anticoagulant: 9 parts blood), as used for other
blood coagulation tests (NCCLS, 1998). Inadequate filling of
the collection tube affects this ratio and leads to inaccurate
results. For haematocrits greater than 0Æ55 l ⁄ l, the final
blood citrate concentration requires adjustment and charts
are available which indicate the amounts of anticoagulant
and blood to be mixed (NCCLS, 1998). It is essential that
blood is collected by clean venepuncture, with minimal
stasis, and as rapidly as possible (Rosenson et al, 1998).
Prior to fibrinogen determination, blood samples should be
inspected by gentle inversion for the presence of clots.
Samples with any evidence of clots or marked haemolysis
should be rejected.
Plasma should be prepared so that platelets are
removed (to a count of < 10 · 109 ⁄ l) by centrifugation
at a minimum of 1700 g for 10 min; this can be
performed at room temperature. Severely lipaemic or
icteric samples may cause analysis difficulties in some
photo-optical methods of fibrinogen measurement. Sam-
ples can be stored at room temperature prior to fibrinogen
determination, for at least 4 h and probably longer. If
more prolonged storage is required, then 4C is a suitable
temperature for Clauss fibrinogen determination, and
storage at 4C for up to 48 h did not affect assay results
in one study (Rosenson et al, 1998). Plasma can be stored
deep frozen for longer periods (Cushman et al, 1995),
preferably at )70C, where it is stable for at least
18 months (Blanco et al, 2000). Storage of samples from
patients with DIC or those receiving thrombolytic therapy
may lead to in vitro proteolysis of fibrinogen unless
suitable protease inhibitors are included in the antico-
agulant. If plasma is frozen prior to analysis, it should be
immediately transferred to a 37C water bath, thawed for
5 min at 37C and mixed by inversion prior to analysis.
Any slow or partial thaw can lead to the formation of
cryo-precipitate, which contains fibrinogen, and thus may
affect the results. For assay of fibrinogen in therapeutic
cryo-precipitate products and other fibrinogen concen-
trates, a full thaw at 37C is necessary followed by
careful mixing to re-suspend the fibrinogen. This material
will normally require a greater dilution than normal
plasma in order to achieve a concentration that can be
successfully assayed by the Clauss technique.
STANDARDS, REFERENCE PREPARATIONS
AND REFERENCE RANGES
Local reference plasmas may be prepared by pooling
plasmas from at least six healthy normal donors and
calibrating against National (British Standard for Blood
Coagulation Factors, Plasma, NIBSC) or International
(Second International Standard for Fibrinogen, Plasma)
standards. These pools should ideally be stored in aliquots at
)70C and completely thawed at 37C before use. If
commercial reference preparations are used, they should
be suitably calibrated; some have shown significant devia-
tions from the International Standard in their potency
estimates (MDA, 1999; Mackie et al, 2002). If commercial
plasmas are used, it is advisable to select preparations with a
good optical clarity wherever possible.
In order to provide reference materials for widespread
use, lyophilization is required to prevent the deterioration of
fibrinogen. Reference plasmas should not be turbid, as this
creates practical problems with the calibration of photo-
optical coagulometers for Clauss and PT-Fg assays. High
fibrinogen concentrations may be incompatible with PT-Fg
calibrations when using certain analysers and reagents.
Purified fibrinogen is generally unsuitable in the prepar-
ation of standard materials for assay in clinical laboratories,
as after its lyophilization there are often problems with
solubility, specific activity, degradation and optical clarity.
Reference ranges should be established in each laborat-
ory, using at least 40 healthy normal subjects, covering a
wide age range and both sexes. Blood samples from patients
should not be used, even if they are free from any major
illness, as it is likely that they will be stressed or may have
an acute phase reaction, which would skew the range of
values.
QUALITY CONTROL
It is recommended that all laboratories participate in an
accredited external quality assessment scheme and investi-
gate any evidence of local problems. For participants in
larger groups, it may be possible to identify methodological
bias related to particular components of the assay (such as
reference plasma or source of reagent) and these should be
Table IV. Pre-test variables.
Anticoagulant Tri-sodium citrate (0Æ105–0Æ109 mol ⁄ l)
Correct filling 9 parts blood to 1 part citrate
Haematocrit Adjust citrate for polycythaemia
Venepuncture Clean, fast, minimal stasis
Blood and plasma inspection Clots, haemolysis, lipaemia, icterus
Platelet depletion Centrifuge > 1700 g, 10 min, < 10 · 109 ⁄ l
Storage 4C for 48 h (unless DIC); )70C for ‡18 months
Freezing and thawing Thaw at 37C for ‡5 min, mix well
Correct dilution Dilute concentrates and plasmas
with high fibrinogen, so that values are
within standard curve limits
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taken into account when selecting a suitably standardized
technique.
An internal quality control (QC) sample, with a normal
fibrinogen level, should be analysed with each group of
fibrinogen determinations (or at intervals of 2–3 h for
continuous processing systems). A QC sample with reduced
or raised fibrinogen may be useful, depending on the
purpose for which fibrinogen assays are being performed, or
if unexpected results are obtained from test samples. A
written record of internal QC results should be maintained
to include the result, time of analysis and reagent batch ⁄ lot
numbers. It is useful to maintain a cumulative record,
preferably as a graph, because this can identify any gradual
drift in QC results, which could indicate that the method is
moving out of the range of the control. If a QC result lies
outside acceptable limits (frequently provided by manufac-
turers as a target range), then patient testing must be
suspended until the problem has been identified and
resolved.
AUDIT
Routine audit of the laboratory measurement and the
clinical utility of fibrinogen assays should be incorporated
into routine practice. The potential variability of laboratory
methodology, involving both reagents and end-point detec-
tion systems, should be regularly examined by participation
in an accredited external quality assessment scheme.
Clinical audit is more complex and should involve the
diagnostic value of a low ⁄normal fibrinogen level in the
investigation of acquired and inherited bleeding disorders,
and also the value of normal ⁄high levels in the risk
assessment of thrombotic cardiovascular disease. For the
investigation of bleeding disorders, a comparison of fibrin-
ogen levels with the thrombin time, the variation during
thrombolytic therapy and the correlation with replacement
therapy (i.e. fibrinogen concentrates) should be studied.
Specific levels of fibrinogen should be defined for further
action, as part of clinical protocols (i.e. the levels following
massive transfusion or acute DIC when specific replace-
ment therapy must be initiated). Risk assessment of
arterial thrombosis is more controversial, but levels of risk
in specific diseases (i.e. myocardial infarction) need to be
defined with actual fibrinogen levels divided into quartiles
(or even quintiles) of the overall normal range. These
ranges could then be discussed with the relevant clini-
cians, so that patients may be counselled as to their overall
risk, specific interventions advised (such as stopping
smoking), and the timing of follow-up measurements
decided. To differentiate high levels from an acute phase
response, comparisons with other acute phase proteins,
particularly C-reactive protein and von Willebrand factor
antigen, can be studied.
CONCLUSIONS
The Clauss fibrinogen assay appears to be the most reliable
method for general use in clinical laboratories. In the UK,
most clinical experience with fibrinogen levels in coagulo-
pathies relates to the Clauss assay and most educational
material is also based on this technique. The PT-Fg method
and immunological techniques may be useful in large
population studies where elevated fibrinogen is sought, but
may not always provide accurate fibrinogen measurements.
For the investigation of congenital dysfibrinogenaemias,
both functional (Clauss or clottable protein assays) and
immunological fibrinogen assays should be performed
(Haverkate & Samama, 1995) to identify any discrepancy
between results.
PT-Fg levels appear to show a false elevation in a variety
of clinical settings and, if the assay is used, it must be
supported by a different functional assay before either
diagnosis or management decisions are made. In light of the
available literature, which shows that the PT-Fg measure-
ment is significantly influenced by the choice of calibrant,
reagent and analyser, the test is not recommended for
routine clinical use.
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